Please use this identifier to cite or link to this item:
http://dspace.hmtu.edu.vn/handle/DHKTYTHD_123/366
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Connolly, Gregory C. | - |
dc.contributor.author | Francis, Charles W. | - |
dc.date.accessioned | 2015-11-30T03:47:54Z | - |
dc.date.available | 2015-11-30T03:47:54Z | - |
dc.date.issued | 2013 | - |
dc.identifier.uri | http://220.231.117.85:8000/handle/DHKTYTHD_123/366 | - |
dc.description.abstract | Cancer-associated thrombosis accounts for almost one-fifth of all cases of venous thromboembolism (VTE) and is a leading cause of death, morbidity, delays in care, and increased costs. Our understanding of risk factors for cancer-associated thrombosis has expanded in recent years, and investigators have begun to use biomarkers and clinical prediction models to identify those cancer patients at greatest risk for VTE. The Khorana Risk Model, which is based on easily obtained biomarkers and clinical factors, has now been validated in several studies. Recent clinical trials of prophylaxis and treatment of VTE in cancer patients are reviewed here. In addition, consensus guidelines and expert opinion regarding management of VTE in specific challenging situations are presented. | vi |
dc.language.iso | en | vi |
dc.publisher | American Society of Hematology | vi |
dc.title | Cancer-associated thrombosis | vi |
dc.type | Article | vi |
Appears in Collections | Huyết học = Hematology |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Hematology-2013-Connolly-684-91.pdf Restricted Access | 171.55 kB | Adobe PDF | Request Item |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.